REGENXBIO’s $1.8 Billion Partnership With AbbVie

McDermott Will & Emery represented REGENXBIO in the transaction.REGENXBIO closed its $1.8 billion strategic partnership with AbbVie to develop and commercialize RGX-314, a potential one-time gene…

This content is for Standard 1 Year members only.
Login Join Now

Kumquat Biosciences’ $1.2 Billion Collaboration and License Agreement with Takeda

Albemarle’s $2.3 Billion Depositary Shares Offering

Surgery Partners’ $800 Million High Yield Senior Notes Offering

Inverfal’s Debt Securities Program

Muon Group’s Registration as Acquirer in Colombia

Gasco’s Project Financing Agreement

Handverksgruppen’s Acquisition of Four Businesses

Lendway’s Acquisition of a Majority Stake Bloomia

Grünenthal Pharma AG’s Win Public Law Litigation in Swiss Federal Supreme Court

KOKO Networks Limited’s Financing Round

India Vehicle Finance’s Notes Offering

Al-Arafa’s Demerger into Concrete Fashion Group and GTEX

SC Ventures’ $100 Million Joint Venture With SBI Holdings

GreenCorp’s Acquisition of Emad Bakeries

MedOne’s Agreement with Shikun and Binui Energy

D3 Bio’s $62 Million Series A Financing Round

Sinopharm Group’s HK$15.6 Billion Privatization Of China TCM

D3 Bio’s $62 Million Series A Financing Round

Paul Hastings Adds Premier Private Equity Buyout Team

BCLP Appoints Trevor Varnes as Chief Financial Officer

B&C Tax strengthens its practice with new partner Daniela Diciaula

The Distinctive Character Of The ‘Vespa’ Is No Longer In Question

Cultural Heritage Sites With Restrictions On Intended Use: The Council of State Acknowledges That This Power Lies In the Hands Of The Ministry Of Culture

The Italian Revenue Agency Qualifies Directors’ Reversible Remuneration For The Purposes Of Double Taxation Agrements.

Paul Hastings Adds Premier Private Equity Buyout Team

BCLP Appoints Trevor Varnes as Chief Financial Officer

B&C Tax strengthens its practice with new partner Daniela Diciaula

REGENXBIO’s $1.8 Billion Partnership With AbbVie

Author: Martina Bellini